Rapport Therapeutics (NASDAQ:RAPP) Shares Down 6.5% – Time to Sell?

Rapport Therapeutics (NASDAQ:RAPP) shares were down 6.5% during mid-day trading on Friday . The stock traded as low as $20.56 and last traded at $20.56. Approximately 5,964 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 157,690 shares. The stock had previously closed at $21.98.

Rapport Therapeutics Stock Performance

The firm’s 50-day simple moving average is $22.56.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Values First Advisors Inc. bought a new stake in Rapport Therapeutics during the 3rd quarter worth approximately $31,000. BNP Paribas Financial Markets purchased a new position in shares of Rapport Therapeutics in the 3rd quarter worth about $34,000. The Manufacturers Life Insurance Company increased its stake in shares of Rapport Therapeutics by 2.4% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 77,344 shares of the company’s stock worth $1,584,000 after purchasing an additional 1,828 shares during the last quarter. SG Americas Securities LLC purchased a new position in Rapport Therapeutics in the third quarter valued at approximately $101,000. Finally, Sandia Investment Management LP purchased a new stake in Rapport Therapeutics in the second quarter worth $116,000.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.